Bone Abstracts

Osteoporosis-related hip fractures represent a substantial cause of mortality and morbidity in industrialized countries; nonetheless, past studies in Austria lack mortality figures save during hospitalization (in-hospital mortality).We therefore retrospectively retrieved pseudonymized invoice data from Austrian social insurance authorities covering roughly 98% of the entire population including 31 548 subjects over 51 years of age who sustained first hip...

Osteoporosis is commonly known as the prime risk factor for hip fracture in the elderly. We thus evaluated status and effect of osteoporosis treatment amongst hip fracture patients in a large Austrian cohort.Retrospectively retrieved pseudonymized invoice data from Austrian social insurance authorities covering roughly 98% of the entire population included 31 548 subjects over 50 years with first hip fractures between July 2008 and December 2010, with fo...

see PP359....

Bisphosphonates (BPs) including alendronate (ALN) are the most widely prescribed therapy for post-menopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, concerns have been expressed lately regarding potential detrimental effects due to prolonged bone turnover reduction, although no definite cause–effect relationship has been established to date. The purpose of the present study was to determine bone material quality by R...

We retrospectively analyzed the incidence of hip re-fractures in Austrian hip fracture patients devoid of anti-osteoporotic drug treatment, taking vs not taking proton pump inhibitors (PPIs).For 31,668 patients ≥50 years sustaining a hip fracture in Austria between July 2008 and December 2010, information on hip re-fractures with follow-up until June 2011 and on filed prescriptions of PPIs and anti-osteoporotic drugs between July 2007 and June 2011...